Drug intelligence / Profile preview

Panamol

Development stage: Unknown
Lead developer: Beacons Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

Panamol is a generic formulation of paracetamol (acetaminophen) manufactured and marketed by Beacons Pharmaceuticals. It is a small molecule analgesic and antipyretic drug indicated for the temporary relief of fever and minor aches and pains. Panamol works primarily by inhibiting cyclooxygenase (COX) enzymes within the central nervous system, which reduces prostaglandin synthesis. Additionally, it acts on the hypothalamic heat-regulating center to produce its antipyretic effect. It is approved as an over-the-counter medicine in Singapore and has been available in the market since 1991, primarily in a 500mg oral tablet form.

Brand names: Panamol
Other names: paracetamolacetaminophen

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on Panamol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Panamol.

Explore the full profile